Loading...
•
Mar 31, 2021
Accuray Q3 2021 Earnings Report
Accuray's financial performance reflected positive momentum despite COVID-19 headwinds, with system revenue conversion in China and FDA clearance for ClearRT Helical kVCT Imaging.
Key Takeaways
Accuray reported a net revenue of $102.6 million for the third quarter of fiscal year 2021, which includes $24.9 million of system revenue in China. The company's GAAP operating income was $4.4 million, but they experienced a net loss of $0.4 million. Gross orders totaled $87.4 million, and the ending backlog increased by 7 percent from the previous year to $610.8 million.
Net revenue reached $102.6 million, including $24.9 million from system revenue in China.
Gross orders amounted to $87.4 million, with an ending backlog of $610.8 million, a 7% increase year-over-year.
GAAP operating income was $4.4 million, while the GAAP net loss was $0.4 million.
FDA clearance was received for ClearRT™ Helical kVCT Imaging for the Radixact® System.
Revenue by Segment
Forward Guidance
Accuray refrained from providing financial guidance for fiscal year 2021 due to the uncertainty surrounding the impact of the COVID-19 pandemic on the global economy and the healthcare industry.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...